By Office of Maryland Attorney Brown
Maryland Attorney General Anthony G. Brown and officials from 16 other states, as well as the District of Columbia, are requesting the U.S. Food and Drug Administration (FDA) remove burdensome restrictions on mifepristone, one of two drugs used in medication abortions, the most common means of abortion in the U.S.
The coalition submitted a filing presenting extensive evidence on the safety of medication abortion as well as the burdens imposed by the FDA’s continued restrictions on mifepristone. In the filing, the states join and supplement a citizen petition filed with the FDA by Massachusetts, California, New Jersey and New York on June 5. The coalition urges the agency to eliminate unnecessary restrictions on this safe medication that make it much harder for patients to access medication abortions, particularly in rural and medically underserved areas.
In response to political pressure to restrict medication abortion, U.S. Health and Human Services Secretary Robert F. Kennedy Jr. told a Senate committee in May that he had ordered the FDA to conduct a “complete review” of mifepristone. Since receiving FDA approval in 2000, the combination of mifepristone and misoprostol has been the only FDA-approved regimen to end an early pregnancy. The safety and efficacy of medication abortion are well established by hundreds of scientific studies and more than 7.5 million women in the U.S. have safely used mifepristone for abortion care or miscarriage management.
And yet, the FDA has set restrictions on the drug not warranted by its long and well-documented history of safety. The FDA requirements for mifepristone unduly burden patient access by, among other things:
- Requiring providers to become a registered prescriber of mifepristone
- Requiring pharmacies to obtain special certification to dispense mifepristone
- Requiring patients to sign a form agreeing that they are voluntarily terminating their pregnancy before they can receive a mifepristone prescription
These extra and unnecessary requirements, which apply to almost no other drugs the FDA regulates, discourage medical professionals from providing medication abortion when they already have the appropriate training to provide the drug.
In the filing, Attorney General Brown and the coalition of attorneys general request that the FDA finally remove these onerous and unnecessary restrictions on mifepristone. Alternatively, they ask the FDA to stop enforcing the requirements in their states because the states already have robust regulatory schemes to ensure patient safety.
Joining Attorney General Brown in submitting the petition to the FDA are the attorneys general of Arizona, Colorado, Connecticut, Delaware, Hawai‘i, Illinois, Maine, Michigan, Minnesota, Nevada, New Mexico, Oregon, Rhode Island, Vermont, the District of Columbia, Washington and Pennsylvania Gov. Josh Shapiro, on behalf of the Commonwealth of Pennsylvania.
Great Job Press Release & the Team @ AFRO American Newspapers Source link for sharing this story.
